1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Plague - Pipeline Review, H1 2016

Plague - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 66 pages

Plague - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Plague - Pipeline Review, H1 2016’, provides an overview of the Plague pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plague and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Plague
- The report reviews pipeline therapeutics for Plague by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Plague therapeutics and enlists all their major and minor projects
- The report assesses Plague therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Plague

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Plague
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Plague pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Plague - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Plague Overview 8
Therapeutics Development 9
Pipeline Products for Plague - Overview 9
Pipeline Products for Plague - Comparative Analysis 10
Plague - Therapeutics under Development by Companies 11
Plague - Therapeutics under Investigation by Universities/Institutes 12
Plague - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Plague - Products under Development by Companies 16
Plague - Products under Investigation by Universities/Institutes 17
Plague - Companies Involved in Therapeutics Development 18
Aradigm Corporation 18
AvidBiotics Corp. 19
Grifols, S.A. 20
iBio, Inc. 21
Mucosis B.V. 22
Syntiron LLC 23
Takeda Pharmaceutical Company Limited 24
Tetraphase Pharmaceuticals Inc. 25
Plague - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
(plague + small pox) vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
anthrax + plague vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
ARD-3100 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
ciprofloxacin hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
plague vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
plague vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
plague vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
plague vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
plague vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
plague vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
plague vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
plague vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
plague vaccine 2 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
pneumonic plaque vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Recombinant Protein for Pneumonic Plague - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Small Molecules to Inhibit Yoph Protein Tyrosine Phosphatase for Plague - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
TP-271 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Yersinia pestis vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Plague - Recent Pipeline Updates 56
Plague - Dormant Projects 60
Plague - Discontinued Products 61
Plague - Product Development Milestones 62
Featured News and Press Releases 62
Mar 30, 2015: iBio European Plague Vaccine Patent Emerges From Opposition Period 62
Nov 19, 2012: UK Scientists Report On Efficacy Of Aradigm's Lipoquin Against Pneumonic Plague 62
May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague 64
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List of Tables
Number of Products under Development for Plague, H1 2016 9
Number of Products under Development for Plague - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Comparative Analysis by Unknown Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Plague - Pipeline by Aradigm Corporation, H1 2016 18
Plague - Pipeline by AvidBiotics Corp., H1 2016 19
Plague - Pipeline by Grifols, S.A., H1 2016 20
Plague - Pipeline by iBio, Inc., H1 2016 21
Plague - Pipeline by Mucosis B.V., H1 2016 22
Plague - Pipeline by Syntiron LLC, H1 2016 23
Plague - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 24
Plague - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Assessment by Combination Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Mechanism of Action, H1 2016 31
Number of Products by Stage and Route of Administration, H1 2016 33
Number of Products by Stage and Molecule Type, H1 2016 35
Plague Therapeutics - Recent Pipeline Updates, H1 2016 56
Plague - Dormant Projects, H1 2016 60
Plague - Discontinued Products, H1 2016 61

List of Figures
Number of Products under Development for Plague, H1 2016 9
Number of Products under Development for Plague - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Targets, H1 2016 28
Number of Products by Stage and Targets, H1 2016 28
Number of Products by Mechanism of Actions, H1 2016 30
Number of Products by Stage and Mechanism of Actions, H1 2016 30
Number of Products by Routes of Administration, H1 2016 32
Number of Products by Stage and Routes of Administration, H1 2016 32
Number of Products by Molecule Types, H1 2016 34
Number of Products by Stage and Molecule Types, H1 2016 34

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016

Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016’, provides in depth analysis on Cell Division ...

Bacterial Conjunctivitis - Pipeline Review, H2 2016

Bacterial Conjunctivitis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Bacterial Conjunctivitis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Pipeline Review, H2 2016, provides ...

Traveler’s Diarrhea - Pipeline Review, H2 2016

Traveler’s Diarrhea - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • August 2016
  • by Global Markets Direct

Traveler’s Diarrhea - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Traveler’s Diarrhea - Pipeline Review, H2 2016’, provides an overview of the Traveler’s Diarrhea pipeline landscape. ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.